After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT),
this therapy has advanced from one that was declared dead in the 1960s to a standard …

''It seems more than ever likely that blood-derived stem tive capacity. 47-49 In the allogeneic
setting, mobilized blood cells have also been used instead of BM. 50 Umbilical cord cells …

Background Randomized trials have shown that the transplantation of filgrastim-mobilized
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but …

For this study, 118 children with standard-risk acute lymphoblastic leukemia (ALL) were
given randomized assignments to receive native or pegylated Escherichia coli asparaginase …

Background In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells
mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating factor) …

Background Bone marrow contains stem cells with the potential to differentiate into mature
cells of various organs. We determined whether circulating stem cells have a similar …

PURPOSE To investigate the use of a nonmyeloablative fludarabine-based preparative
regimen to produce sufficient immunosuppression to allow engraftment of allogeneic stem …

2000 update of recommendations for the use of hematopoietic colony-stimulating factors:
evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth …

Peripheral blood cells are increasingly used in place of bone marrow as a source of
hematopoietic stem cells for allogeneic transplantation. The relative efficacy of these 2 …

More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each
year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital …